NCT04300556: A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 182 planned
- Started
- 6 Aug 2020
- Primary completion
- 8 Aug 2030
- Arms
- Dose Escalation Part: Farletuzumab ecteribulin, Dose Confirmation Part: Farletuzumab ecteribulin, Dose Optimization Part A, Cohort 2: Farletuzumab ecteribulin, Dose Optimization Part A, Cohort 3: Farletuzumab ecteribulin
- Results
- None posted
- 9 Mar 2020: Trial registered
- 6 Aug 2020: Trial started